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ABSTRACT 
Objective: The main objective of this research was to explore the effect of the polar fraction of tubers of Pueraria tuberosa (PTWE) on DPP-IV activity.  
Methods: The comparison of in vitro inhibitory potential between commercially available Galvus (Vildagliptin) and PTWE was determined by 
measuring percent inhibition and IC50.
Results: PTWE has given the IC
 The enzyme kinetics were also done to reveal the nature of inhibition. In vivo study was done via the glucose 
tolerance test and by the measurement of increased plasma GLP-1 concentration and DPP-IV activity after glucose load. 
50 
Conclusion: These findings suggest that antidiabetic effect of PTWE could be because of its role in DPP-IV inhibition.  
value of 17.4 mg/ml and was found to be a competitive inhibitor having the Ki value of 13.11 mg/ml. Plasma GLP-
1 concentration was increased and DPP-IV activity was decreased after 60 min of glucose load in PTWE treated rats as compared to control rats. 
Overall PTWE was found to be less potential DPP-IV inhibitor than Galvus. 
Keywords: Glucose tolerance, Pueraria tuberosa, DPP-IV, GLP-1, Enzyme Kinetics. 
 
INTRODUCTION 
Metabolic diseases like diabetes and obesity have increased 
consistently in this era. Increased fat intake, decrease in consumption 
of dietary fibers and lifestyle could be the most prominent reason for 
the incidence of these disorders [2]. Nature has given us many 
homeostatic strategies to regulate many pathways in order to 
maintain our body. Secretion of incretin hormones through systemic 
function of an intestine in order to regulate the glucose concentration 
in the blood is one of the homeostatic mechanisms. This mechanism of 
incretin effect is found to be less effective in diabetic patients [6]. So, 
incretin hormones are one of the recent therapies, applied in the 
treatment of diabetes around the world. It is released in the small 
bowel and its function in the regulation of endocrine pancreatic 
secretion is very easily played by intestine [1].  
GLP-1 is one of the incretin hormones released from the intestine in 
response to the passage of the meal through the gastrointestinal 
tract; this event is known as incretin effect. It is a 30 amino acid 
peptide derived from proglucagon through post translational 
processing in enteroendocrine L cells, mainly in the distal ileum and 
colon. Increase in prohormone-convertase (PC) expression in L cells 
is responsible for the production of more active incretin hormones 
because this enzyme is responsible for conversion of proglucagon to 
incretin hormones [10, 11]. GLP-1 is also responsible for the 
reduction of apoptosis of β-cell of the pancreas, thus enhancing its 
expression [12], reducing appetite and slowing gastric emptying 
[14]. GLP-1 has a circulating half-life of only a few min because it is 
extremely vulnerable to the catalytic activity of the proteolytic 
enzyme dipeptidyl peptidase-4 (DPP-IV), which preferentially 
cleaves peptides with the amino acid alanine or proline in position 2 
of the NH2
MATERIALS AND METHODS  
-terminal amino acid, thus makes it inactive. Thus, two 
main incretin based therapeutic approaches are in clinical practice 
in the treatment of type 2 diabetes mellitus i.e. GLP-1 agonists e. g. 
Exenatide and DPP-IV inhibitors [3, 4, 6, 12]. Vildagliptin, Sitagliptin 
and Saxagliptin are few commercial DPP-IV inhibitors available in 
the market, have many undesirable side effects [8]. In order to 
reduce these side effects many researchers are focusing on 
medicinal plants like berry, citrus [24], Berberis aristata [7], 
Mangifera indica [18] or their compounds like flavonoids [23, 24], 
berberine [1] etc. which are helpful to increase the potency of 
incretin secretion. In Ayurveda, an ancient system of Indian 
medicine, Pueraria tuberosa are in clinical use as anti aging drug 
[22], anti-inflammatory [20], antioxidant [19] and as hypoglycemic 
drug [21]. Pueraria tuberosa tubers are rich in steroid, triterpenoid, 
glycoside, carbohydrate, alkaloids, flavanoid, tannin, protein and 
amino acids [21]. We hypothesized that the augmentation of incretin 
hormones could be one of the mechanisms of its hypoglycemic 
potential. Thus, the hypoglycemic effect of PTWE has been checked 
on the incretin based study through both in vivo and in vitro test 
models.  
Chemicals and materials used 
GLP-1 Enzyme Immunoassay (EIA) Kit and Gly-pro-p-nitroanilide 
(GPPN) was purchased from Sigma Aldrich, Galvus-Novartis 
(containing 50 mg Vildagliptin per tablet) was purchased from local 
markets, and other chemicals were of AR grade.  
Sample preparation 
Pueraria tuberosa roots were purchased from Ayurvedic pharmacy, 
Banaras Hindu University. Its 30 g powder was extracted with 8 
volumes of distilled water. When the volume was reduced to ¼, it 
was filtered with cloth. The total yield obtained by this process was 
30%. These waters extract (PTWE) was used for both in vitro and in 
vivo studies. 
Enzyme preparation 
The protocol was approved by the Institute Ethical Committee, 
Institute of Medical Sciences, Banaras Hindu University. The animals 
were sacrificed and the small intestine was isolated. It was cut 
longitudinally and an inner part was gently cleaned and cut into 
small pieces (1 inch.) and frozen at-20o
In vitro study 
 C. One piece was defrosted 
and homogenized in ice cold PBS to make 20% homogenate (as DPP-
IV enzyme source) in glass Teflon Homogenizer. The protein was 
estimated by the Bradford method.  
DPP-IV inhibition assay 
Different concentrations of PTWE were prepared by dilution with 
Tris HCl (50 mM, pH 7.5) and their 10 µl was mixed with 25 µl of 
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Tris-HCl (50 mM, pH 7.5) and 15 µl intestine homogenate in the 96 
well plate. The above mixtures were pre-incubated for 10 min at 
room temperature to enhance the binding capacity of the inhibitor 
and then 50 µl of 0.2 mM substrate (Gly-pro-p-nitroanilide) was 
added to each well and absorbance was taken at 405 nm, 
immediately and after 20 min. All reactions were performed in 
triplicate. Percent inhibition was calculated by using the formula 
given below:  
% Inhibition 
=  
change in O. D of control in 20 min− change in OD of extract in 20 min
Change in OD of control in 20 min  x100 
Inhibition kinetics 
The above experiment was repeated at various concentrations of the 
substrate as shown in Fig.1.  
In vivo 
Animal design 
Eighteen Charles foster albino rats nearly 3-4 months old of 80-100 g 
were divided into three groups (n=6) viz. group 1 for Control, group 
2 for PTWE and group 3 for Galvus as positive control. Rats were 
kept in fasting for 8 hours.  
Glucose tolerance test 
The basal blood of rats was collected in EDTA containing tubes 
after giving anesthesia. Then they were given drugs orally at the 
concentration of 50 mg/100 g bw (PTWE) and 30 mg/100 g bw 
(Galvus).  
After 2 hours of treatment with drugs, all rats of each group have 
given glucose orally at the concentration of 2.5 g/kg bw. Blood 
was again collected at 30 min. and 60 min. following glucose 
load. Glucose concentration in blood was determined by the 
glucose strip (Dr. Morepen) at every step of blood collection.  
GLP-1 concentration in plasma 
GLP-1 concentration in blood plasma was measured by GLP-1 
Enzyme Immunoassay (EIA) Kit.  
DPP-IV activity in plasma 
DPP-IV activity was done by adding 95 µl GPPN (0.2 mM) as 
substrate in the mixture of 65 µl Tris HCl (50 mM, 7.5pH) and 10 µl 
collected blood plasma as DPP-IV enzyme source. Absorbance was 
taken immediately and after 20 min at 405 nm. 
Statistical analysis 
Statistical analysis was determined by one way ANOVA following 
post hoc test using dunnetts and tuckey by IBM SPSS Statistics 
Software. Enzyme kinetics were analyzed by the graph pad prism 
and sigma plot softwares. The information for kinetics analysis was 
based on Akaike criterion (AIC). 
RESULTS 
Inhibition potential 
Galvus as a positive control was found to be more potent DPP-IV 
inhibitor than PTWE in vitro (table 1) given 3.48 fold lower IC50 
Inhibition kinetics 
(calculated using the linear regression equation) than PTWE. 
It has already been reported in previous papers that Galvus 
(Vildagliptin) is a reversible competitive inhibitor of DPP-IV [8]. 
Through in vitro analysis by the graph pad prism and sigma plot, 
PTWE was also found to be a competitive inhibitor (Fig.1) having 
Vmax (5.931 U/mg), Km (207.7 µM), Ki (13.11 mg/ml) and Kcat 
(28.6 x 10-3). The Vmax, Km, Ki and Kcat value for galvus is 1.124 
U/mg, 190.7 µM, 4.232 mg/ml and 5.9 x 10-3
 
. Therefore, the catalytic 
efficiency (Kcat/Km) of an enzyme is 4.43 fold greater in PTWE 
inhibited reactions and also having 3 fold greater Ki compared to 
galvus inhibited reactions (table 1). 
Table 1: Comparison of efficacy between PTWE and Galvus at various concentrations as DPP-IV inhibitor on the basis of percent 
inhibition, IC50, 
Sample 
Vmax, Km, Kcat, Kcat/Km and Ki 
Conc. 
(mg/ml) 
Inhibition (%)  ICa 
(mg/ml) 
50 Vmax (U/mg) Km (µM) Kcat  
(Vmax/Km) 
Kcat/Km Ki (mg/ml) 
 
PTWE 











-5 13.11  15  47±2.8 
 20  55±3.5 
 
Galvus 











-5 4.232  15  70±4.2 
 20  90±4.9 
Notes: a
 
Plasma DPP-IV activity 
DPP-IV activity in plasma of PTWE treated rats were much higher 
than Galvus treated rats, but was found to be significantly reduced 
than untreated rats (table 2 and fig. 2). 
Glucose tolerance test 
Values are the mean of three replicates±SEM 
As compared to control, PTWE decreases plasma glucose 
concentration during 60 min. after glucose load (table 2 and fig. 2). 
Plasma glucose AUC(0-60 min)
Plasma GLP-1 concentration 
 decreased by 27.68 % in PTWE treated 
and 40.63 % in Galvus treated rats as compared to control rats. 
Increase in plasma GLP-1 concentration was found to be 1.2 fold in 
PTWE and 1.4 fold in Galvus treated rats as compared to control rats 
(table 2 and fig. 2). 
Statistical results 
The P value of all data done via one way ANOVA following post hoc 
(Dunnett and Tuckey) is significant at the level of 0.05 both in 
between each group of each parameter and also in between all 
parameters (Glucose, GLP-1 and in vivo DPP-IV activity). 
 
Table 2: Effect of PTWE on glucose tolerance, GLP-1 concentration and DPP-IV activity in blood plasma 
Sample Concentration Glucose Concentration 
(AUC
GLP-1 Concentration (Percentage 
increase in 60 min). 0-60 min) 
DPP-IV Activity (Percentage 
increase in 60 min.) 
Control ------ 6720±109.50 * 65.69±4.1 * 38.10±1.3 * 
PTWE 50 mg/100 g 
bw 
4860±132.67 * 79.65±3.9 * 34.88±1.4 * 
Galvus 30 mg/100 g 
bw 
3990±99.43 * 93.82±4.5 * -30.56±1.5 * 
Notes: P value significant at the 0.05 level (2-tailed)* by Post hoc test using dunnetts and tuckey. 
Tripathi et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 9, 227-231 
229 
A. MM plot for PTWE












   
   
   







            B. LB plot for PTWE




























C. MM plot for Galvus












   
   
   
   







         D. LB plot for Galvus




























Fig. 1: Inhibition Kinetic study of both PTWE and Galvus; a: MM plot for PTWE, b: LB plot for PTWE, c: MM plot for Galvus and d: LB plot for 
Galvus. PTWE was also found to be a competitive inhibitor like Galvus having Vmax (5.931 U/mg), Km (207.7 µM), Ki (13.11 mg/ml) and 




















































































Fig. 2: In vivo study a: Glucose tolerance (n=6, P<0.05), b: AUC(0-60 min) of glucose concentration (n=6, P<0.05), c: Percent increase in plasma 
GLP-1 concentration after one hour of glucose consumption (n=6, P<0.05), d: Percent decrease in plasma DPP-IV activity after one hour of 
glucose consumption (n=6, P<0.05) 
Tripathi et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 9, 227-231 
230 
DISCUSSION 
According to our results, the hypoglycemic role of PTWE has been 
found to be contributed by the mechanism of incretin hormones 
secretions. The DPP-IV activity in plasma was decreased, which 
leads to increase in overall plasma GLP-1 concentration and glucose 
tolerance in PTWE treated rats in comparison to control rats. 
Therefore, enhanced glucose tolerance must be because of the 
greater proportion of the active form of GLP-1 rather than the 
inactive form of GLP-1. This active form must have acted on β-cells 
of the pancreas in order to release insulin. PTWE is a competitive 
inhibitor of DPP-IV enzyme (fig. 1), so it can reduce the enzyme 
catalytic efficiency by binding directly to the active site of enzyme 
thus making no effect on Vmax, but will increase Km.  
Increase in Km means a reduction in binding affinity of an enzyme 
for its substrate. Binding directly to the active site of an enzyme by 
PTWE leads us to the conclusion that it should have any component 
which must have a structure that resembles with the structure of the 
substrate of DPP-IV enzyme. PTWE did not reduce as much plasma 
DPP-IV activity after 60 min. as compared to Galvus (Fig.2), but it 
could be possible that the reduction in gut DPP-IV activity might 
have played the major role in enhancing GLP-1 secretion [16], thus 
enhancing glucose tolerance. As mentioned earlier PTWE contains 
flavonoids, which were already known to have both DPP-IV 
inhibitory action [24] as well as the ability to potentiate incretin 
hormone secretion by acting as a GLP-1 receptor agonist [23]. 
According to previous results, flavones is a competitive inhibitor of 
DPP-IV [24]. Thus, flavonoids might be the most probable reason 
why this plant tuber helps in enhancing glucose tolerance and GLP-1 
secretion. Of many naturally occurring flavonoids, only a few have 
been reported to have DPP-IV inhibitory effect [25,26].  
So, which flavonoids of PTWE and by which structure does it 
enhance incretin secretion either as DPP-IV inhibitor to increase 
GLP-1 half-life or as incretin agonist to modify GLP-1R binding and 
signalling through cAMP formation and intracellular 
Ca2+
CONCLUSION 
mobilization [23] could also be taken as one of the interesting 
study in order to reveal the mechanism of action. We have taken 
PTWE (the water extract of Pueraria tuberosa), which must have 
contained many types of component. Hence, we cannot just focus 
ourselves specifically to the flavonoids as only the responsible 
components, other components could also have more or less effect 
on this approach either individually or synchronously with others. 
Consumption of medicinal plants as a whole must be more effective 
than the isolated components to the patients because of the 
presence of various beneficial ingredients, so they can effect in many 
ways to maintain health of the individual. Thus, this kind of crude 
extract study should also be done prior to specific studies. Questions 
like, through which approach and by what mechanism and on which 
part of an intestine or any other organs does this plant is acting on, 
can be revealed by proper study on the level of cell and molecular 
biology.  
PTWE as DPP-IV inhibitor could be helpful in the treatment of 
diabetes as it enhances the half-life of active GLP-1 which leads to 
regulate glucose dependent insulin secretion by β-cell of the 
pancreas through inhibition of DPP-IV in vivo. On the other hand 
PTWE is also having no or less side effects and economically 
beneficial and also having many other medicinal properties which 
could be more helpful to diabetic patients as compared to 
commercially available DPP-IV inhibitors.  
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